China Securities Intelligent Finance Guizhou Bailing(002424) announced on the evening of October 15 that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., received the "Notice of Approval of Drug Clinical Trial" approved and issued by the National Medical Products Administration (NMPA). The clinical trial application for Tangning Tongluo Tablets submitted by Bailing Yuxiu was approved, and it was agreed that this product would be used for clinical trials in type 2 diabetes.
　　The announcement indicates that this product, which received clinical trial approval in 2024 for non-proliferative diabetic retinopathy (yin deficiency, internal heat, and eye meridian stasis), is currently applying to add an indication for type 2 diabetes (damp-heat accumulation syndrome) during clinical trials. The information states that Tangning Tongluo Tablets were prepared by a medical institution in Guizhou Province, and summary reports from three previous clinical studies have been provided. This Phase II clinical trial will fully explore the characteristics of the product's applicable population and effectiveness, providing support for the design of subsequent clinical trial protocols.
　　The company stated that Miao medicine, as an integral part of Guizhou's intangible culture, is a valuable asset for its development, with its unique therapeutic effects and profound cultural heritage. The approval of Tangning Tongluo Tablets for clinical trials in type 2 diabetes represents a significant achievement in the company's integrated Miao medicine program. As a leading Miao medicine company, the company will remain committed to the preservation and innovation of Miao medicine, leveraging modern technology to continuously explore and integrate its unique value and transform it into more high-quality products and services.
Guizhou Bailing is a publicly listed pharmaceutical company 　　specializing in the research, development, production, and sales of Miao medicine. In the first half of 2025, the company achieved operating revenue of 1.462 billion yuan and net profit attributable to parent company shareholders of 51.8346 million yuan.

https://finance.eastmoney.com/a/202510153535068639.html